Germany-based CureVac has reportedly rejected a proposal by the Trump administration to purchase the exclusive rights to a coronavirus vaccine.
According to the German news source Mannheimer Morgen, Trump offered funds to lure CureVac to the U.S., and the German government was making counter-offers to tempt the biotech to stay.
Richard Grenell, acting Director of National Intelligence and the U.S. Ambassador to Germany, later said the newspaper report was untrue.
CureVac posted a press release stating, "The company is in contact with especially CEPI and many other organizations and authorities worldwide, however abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology."
According to CureVac, internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people worldwide.